Skip to Content
Cancer Diagnosis Program
Contact NExT
Show menu
Search this site
Last Updated: 01/13/20

Current Funding Opportunities

The Requests for Applications (RFAs) and Program Announcements (PAs) listed below communicate CDP’s current funding opportunities and research interests. CDP staff contacts and published notices are provided in the summary link for each opportunity. We encourage you to discuss your proposed research with a CDP program director before you submit an application. This page updates to reflect the active Funding Opportunities.

To receive email updates, click here or follow us on Twitter.

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 — Clinical Trial Optional): PAR-18-530

Re-issue of PAR 15-075
Posted date: December 21, 2017;
Expiration date: January 8, 2021
Application receipt dates: March 8, 2018; thereafter, standard application dates apply.

This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status.

See full announcement on grants.nih.gov

National Cancer Institute’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required): PAR-18-560

Posted date: January 5, 2018;
Expiration date: January 8, 2021
Application receipt dates: March 15, 2018; thereafter, standard application dates apply.

The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD). Applicants are strongly encouraged to consult the NCI DCTD website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA.

CDP contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov
See full announcement on grants.nih.gov

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) PAR-19-356

Posted date: August 28, 2019;
Expiration date: July 21, 2022
Application receipt dates: February 20, 2020, June 19, 2020; October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Assay Validation of High Quality Markers for Clinical Studies in Cancer: PAR-18-317 (UH2/UH3 Clinical Trial Not Allowed)

Reissue of PAR-15-095. Posted date: October 13, 2017;
Expiration date: October 9, 2020.
Application receipt dates: February 14, 2018; July 10, 2018; October 8, 2018; February 13, 2019; July 10, 2019; October 8, 2019; February 13, 2020; July 10, 2020; October 8, 2020, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Assay Validation for High Quality Markers for Clinical Studies in Cancer (UH3) (Clinical Trials Not Allowed): PAR-18-310

Release/Posted date: October 13, 2017
Expiration Date: October 9, 2020
Application receipt dates: February 14, 2018; July 10, 2018; October 8, 2018; February 13, 2019; July 10, 2019; October 8, 2019; February 13, 2020; July 10, 2020; October 8, 2020, by 5:00 PM local time of applicant organization

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Contact Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov

Informatics Technology for Cancer Research (ITCR) Program (http://itcr.nci.nih.gov/)

ITCR supports a wide range of informatics tools to serve current and emerging needs across the cancer research continuum.

Algorithm Development: PAR-15-334 (R21):

Expired: Pending Reissuance

This FOA supports the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum.

CDP contact: Dr. Aniruddha Ganguly, gangulya@mail.nih.gov

Prototyping and Hardening: PAR-15-332 (U01):

Expired: Pending Reissuance

This FOA supports the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in support of cancer research.

CDP contact: Dr. Aniruddha Ganguly, gangulya@mail.nih.gov

Enhancement and Dissemination: PAR-15-331 (U24):

Expired: Pending Reissuance

This FOA supports the advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in support of cancer research.

Sustainment: PAR-15-333 (U24):

Expired: Pending Reissuance

This FOA supports the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum.

CDP contact: Dr. Aniruddha Ganguly, gangulya@mail.nih.gov

Bioengineering Technologies

The NIH bioengineering program supports basic, applied, and translational bioengineering research that addresses important biological or medical research problems.

CDP contact: Mr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Exploratory/Developmental Bioengineering Research Grants [EBRG]:]: PA-19-149 (R21 clinical trial not allowed)

Release/Posted Date: January 8, 2019
Expiration date: January 8, 2022
Application Receipt Dates: standard receipt dates for non-AIDS applications; standard AIDS dates for AIDS applications

The EBRGs support early bioengineering research. EBRG applications may contain minimal or no preliminary data, and may propose hypothesis-driven, discovery-driven or design-directed research.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Bioengineering Research Grants [BRG]: PAR-19-158 (R01 Clinical Trial Not Allowed)

Posted Date: January 8, 2019;
Expiration date: January 8, 2022
Application Receipt Dates: May 7, 2019; thereafter standard receipt dates apply; standard AIDS dates for AIDS applications

The purpose of this FOA is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Bioengineering Research Grants [BRG]: PAR-19-158 (R01 Clinical Trial Required, companion to PAR-19-158)

Posted Date: January 8, 2019;
Expiration date: May 8, 2021
Application Receipt Dates: May 7, 2019; thereafter standard receipt dates apply; standard AIDS dates for AIDS applications

The purpose of this FOA is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

Bioengineering Research Partnerships [BRP]: PAR-19-150 (R21 clinical trial optional)

Release/Posted Date: January 8, 2019;
Expiration date: January 8, 2022
Application Receipt Dates: standard receipt dates for non-AIDS applications; standard AIDS dates for AIDS applications

The BRPs support large basic, applied, and translational multi-disciplinary research performed by multiple organizations that applies an integrative approach, which includes bioengineering and biomedical/clinical components.

CDP contact: Dr. Miguel Ossandon, 240-276-5714, ossandom@mail.nih.gov

FOR THE LATEST INFORMATION ABOUT NCI INITIATIVES, VISIT
Division of Extramural Activities, National Cancer Institute
http://deainfo.nci.nih.gov/funding.htm

National Institutes of Health
U.S. Department of Health and Human Services